Pharmacogenetics and epilepsy; analyse van de respons op lamotrigine

Phase 4

Withdrawn

• Conditions: epilepsy; 10039911

• Registration Number: NL-OMON29964
• Lead Sponsor: Stichting Epilepsie Instellingen Nederland (SEIN)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 18 June 2024

Recruitment & Eligibility

• Status: Withdrawn
• Sex: Not specified
• Target Recruitment: 200

Inclusion Criteria

General inclusion criteria
1. Adult patients with cryptogenic or symptomatic localization-related epilepsy, manifesting in generalized tonic-clonic, complex partial and/or simple partial seizures.
2. Patients that are able to understand the written information about the study and are able to give informed consent.

Exclusion Criteria

1. Patients failing valproate due to other reasons than persisting seizures despite a maximum tolerated dose (i.e. failure due to adverse effects on a starting dose of valproate, failure due to non-compliance etc).
2. Patients with generalized epilepsy and/or generalized absence-seizures and /or myoclonic seizures.
3. Acute or progressive neurological disease.
4. History of psychiatric disease or substance addiction.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Presence of selected polymorphisms in the three patient groups. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Number of antiepileptic drugs used; epilepsy subtype; seizure type. </p><br>